SARASOTA, Fla., Dec. 23 CPC of America, Inc.(OTC Bulletin Board: CPCF.OB), a company focused on the development oftherapeutic devices that enhance the quality of patient care in endovascularprocedures, announced the addition of three medical and technical advisors toits team. Dr. Olexander Hnojewyj, Dr. James L. Rogers and Richard E. Andersonwill add strategically important bench strengths to the team's expertise asthey work to develop MedClose(TM), an investigational*-stage vascular closuresystem (VCS) that is intended to seal the femoral arterial puncture sitefollowing diagnostic or interventional catheterization procedures. Informationon CPC's advisory team can be found at CPC's enhanced corporate Web site,CPCMedDevices.com.
As a medical advisor, Olexander Hnojewyj, Ph.D. will add deep experienceto the team, in the development of medical devices used in the treatment ofvascular disease. Over the past seven years, he has conducted extensiveresearch related to vascular closure sealants and has secured multiple patentsand patent applications related to vascular closure.
As Bio-Statistician, James L. Rogers, Ph.D. will oversee clinical datamanagement and statistical analysis for international clinical trials for theMedClose(TM) VCS. Dr. Rogers has handled numerous pre-clinical, clinical andpost-approval trials for leading US and European pharmaceutical and medicaldevice companies.
Richard E. Anderson will play a pivotal role as CPC looks to secure ISOand EN certification. He holds more than 30 years of experience in qualityassurance and regulatory affairs. He has worked with numerous early-stagedevice companies to design systems that enhance the quality, productivity andefficiency of manufacturing and has also worked with a variety of regulatorybodies, including the FDA and European Notified Bodies and CompetentAuthorities.
"As we build our operational capabilities, the newest additions to ourteam of advisors are vital to our future success," said Rod Shipman, chairmanand chief executive officer of CPC of America. "With the combined expertiseand experience of our medical, technical and research advisors, we are in astrong position to pursue global commercialization of the MedClose(TM) VCS inan effort to provide a safe, reliable closure system that reduces time tohemostasis and allows for faster patient ambulation and, when necessary, woundre-access."
CPC of America develops therapeutic devices for use in endovascularprocedures. CPC's current focus is the completion of development and testingof the MedClose(TM) vascular closure system, an internal puncture-closingsystem for use in catheter laboratories.
Forward Looking Statements
The statements contained in this press release that are not historical are"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933, as amended (the "Securities Act"), and Section 21E ofthe Securities Exchange Act of 1934, as amended (the "Exchange Act"),including statements, without limitation, regarding the Company'sexpectations, beliefs, intentions or strategies regarding the future. Suchforward-looking statements relate to, among other things: (1) the Company'scontinuing development of its MedClose(TM) vascular closure system, (2) theCompany's expectations concerning regulatory approvals of the MedClose systemand the commencement of revenue producing operations based on the sale orlicensing of the MedClose, (3) the business relationship between the Companyand new parties and the expected benefits to the Company from suchrelationship, and (4) the commencement of manufacturing of the MedClosesystem. These statements are qualified by important factors that could causethe Company's actual results to differ materially from those reflected by theforward-looking statements. Such factors include but are not limited to: (1)the Company's ability to finance the continued development and commencement ofmanufacturing of the MedClose system, (2) regulatory approvals of theMedClose system, (3) the general risks and uncertainties inherent in any newbusiness relationship such as the one recently entered into between theCompany and its new consultants, and (4) those other risks and factorsdescribed from time to time in the Company's reports filed with the Securitiesand Exchange Commission, including but not limited to the Company's AnnualReport on Form 10-K for the year ended December 31, 2007 and subsequentlyfiled Forms 10-Q and Forms 8-K. The Company cautions readers not to placeundue reliance on any forward-looking statements. The Company does notundertake, and specifically disclaims any obligation, to update or revise suchstatements to reflect new circumstances or unanticipated events as they occur
SOURCE CPC of America, Inc.